| Literature DB >> 12154380 |
Alain Fischer1, Salima Hacein-Bey, Marina Cavazzana-Calvo.
Abstract
The concept that the outcome of a devastating disease can be modified by inserting a transgene into abnormal cells is appealing. However, the gene-transfer technologies that are available at present have limited the success of gene therapy so far. Nevertheless, severe combined immunodeficiencies are a useful model, because gene transfer can confer a selective advantage to transduced cells. In this way, a proof of concept for gene therapy has been provided.Entities:
Mesh:
Substances:
Year: 2002 PMID: 12154380 DOI: 10.1038/nri859
Source DB: PubMed Journal: Nat Rev Immunol ISSN: 1474-1733 Impact factor: 53.106